246 related articles for article (PubMed ID: 36963632)
1. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
[TBL] [Abstract][Full Text] [Related]
2. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
Risovic I; Dumanovic MS; Bojic M; Djekic D
BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
[TBL] [Abstract][Full Text] [Related]
4. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
Lisco G; De Tullio A; Guastamacchia E; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
[TBL] [Abstract][Full Text] [Related]
5. An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.
Novodvorský P; Haluzík M
Expert Opin Drug Saf; 2022 Mar; 21(3):349-361. PubMed ID: 34641742
[TBL] [Abstract][Full Text] [Related]
6. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
Goldman J; Trujillo JM
Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
[TBL] [Abstract][Full Text] [Related]
7. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
Singh S; Wright EE; Kwan AY; Thompson JC; Syed IA; Korol EE; Waser NA; Yu MB; Juneja R
Diabetes Obes Metab; 2017 Feb; 19(2):228-238. PubMed ID: 27717130
[TBL] [Abstract][Full Text] [Related]
9. Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
Bajaj HS; Chu L; Bansal N; Brown RE; Dhillon G; Gupta R; Bhela JS; Padda JK; Khandwala H; Venn K; Aronson R
Can J Diabetes; 2022 Jul; 46(5):495-502. PubMed ID: 35752566
[TBL] [Abstract][Full Text] [Related]
10. Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.
Kaneto H; Koshida R; Baxter M
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():24-34. PubMed ID: 32436323
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Home PD; Aroda VR; Blonde L; Guyot P; Shaunik A; Fazeli MS; Goswami H; Kalra S; Pourrahmat MM
Diabetes Obes Metab; 2020 Nov; 22(11):2170-2178. PubMed ID: 32627297
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
Home P; Blonde L; Kalra S; Ji L; Guyot P; Brulle-Wohlhueter C; Murray E; Shah R; Sayre T; Shaunik A
Diabetes Obes Metab; 2020 Nov; 22(11):2179-2188. PubMed ID: 32700442
[TBL] [Abstract][Full Text] [Related]
14. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.
Cai X; Gao X; Yang W; Ji L
Expert Opin Pharmacother; 2017 Dec; 18(17):1789-1798. PubMed ID: 29090600
[TBL] [Abstract][Full Text] [Related]
15. EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
Mora PF; Chao J; Saremi A; Dex TA; Roberts M; Umpierrez GE
Endocr Pract; 2019 Nov; 25(11):1091-1100. PubMed ID: 31241362
[No Abstract] [Full Text] [Related]
16. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
Blonde L; Bailey TS; Chao J; Dex TA; Frias JP; Meneghini LF; Roberts M; Aroda VR
Adv Ther; 2019 Sep; 36(9):2310-2326. PubMed ID: 31359368
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.
Wang R; Luo S; Xiao Z; Zhou Z
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3752. PubMed ID: 38013215
[TBL] [Abstract][Full Text] [Related]
18. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
Skolnik N; Dupree RS; Johnson EL
Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.
Harris K; Nealy KL
Ann Pharmacother; 2018 Jan; 52(1):69-77. PubMed ID: 28799414
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M; Sadeghi M; Barzkar F; Maghsoomi Z; Janani L; Motevalian SA; Loke YK; Ismail-Beigi F; Baradaran HR; Khamseh ME
Front Endocrinol (Lausanne); 2024; 15():1286827. PubMed ID: 38586456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
